The leukemia survival rate in children is now one of the great success stories of modern medicine. In high-income countries, roughly 9 in 10 children with acute lymphoblastic leukemia (ALL), the most common type, survive at least five years, and most of them are cured. Survival for acute myeloid leukemia (AML) is lower, at around two-thirds, but it too has improved steadily.
These numbers reflect decades of careful research, better diagnosis, and much better supportive care. In this article I explain what the survival figures mean, which factors shape an individual child’s outlook, and what advances have driven the progress.
What Is Pediatric Leukemia?
Leukemia is a cancer of the blood-forming cells in the bone marrow. Immature cells called blasts multiply out of control and crowd out normal production, leading to too many abnormal white blood cells and too few healthy red cells and platelets. It is the most common cancer of childhood.
Most pediatric leukemia is acute, meaning it develops quickly. ALL makes up about three-quarters of cases and peaks between ages 2 and 5. AML accounts for most of the rest. Chronic leukemias, such as chronic myeloid leukemia, are rare in children.
Leukemia Survival Rates in Children at a Glance
A five-year survival rate is the share of children alive five years after diagnosis. In childhood ALL, most relapses happen within the first few years, so a child who is in remission at five years is very likely cured.
| Type | Share of childhood leukemia | Approximate 5-year survival (high-income countries) |
|---|---|---|
| Acute lymphoblastic leukemia (ALL) | About 3 in 4 cases | Around 90% |
| Acute myeloid leukemia (AML) | Most of the remainder | Around two-thirds |
| Infant ALL (under 1 year) | Small minority | Lower than other ALL |
In the early 1960s, very few children with ALL survived. The change since then did not come from one breakthrough. It came from many carefully run cooperative trials that refined each phase of treatment, one step at a time. For an adult and pediatric overview, see our article on leukemia survival rates.
Keep in mind that these are population averages. They describe large groups of children treated in the past and cannot predict any single child’s outcome.
Factors That Affect a Child’s Prognosis
Doctors sort children into risk groups so that each child gets enough treatment to cure the leukemia without unnecessary side effects.
| Factor | More favorable | Less favorable |
|---|---|---|
| Age at diagnosis (ALL) | 1 to 9 years | Under 1 year, or 10 and older |
| White blood cell count at diagnosis | Below 50,000 per microliter | 50,000 per microliter or more |
| Leukemia genetics (ALL) | High hyperdiploidy, ETV6-RUNX1 | KMT2A (11q23) rearrangements, low hypodiploidy |
| Response to first treatment | No detectable disease after induction | Measurable residual disease remains |
| Spread to brain or spinal fluid | Absent | Present |
The most powerful factor today is measurable residual disease (MRD): how many leukemia cells remain after the first month of treatment, measured with very sensitive lab tests. Children who clear their disease quickly do best.
Causes and Risk Factors
Most childhood leukemia has no identifiable cause, and nothing parents did or failed to do causes it. Known risk factors include Down syndrome, inherited bone marrow disorders such as Fanconi anemia, high-dose ionizing radiation, and previous chemotherapy. More detail is in our guide to leukemia in children.
Recognizing and Diagnosing Leukemia Early
Early symptoms often look like common childhood illnesses: tiredness, pallor, fever, frequent infections, bone or joint pain, and easy bruising in children with leukemia. These reflect hematological problems such as anemia and low platelets.
Diagnosing leukemia starts with a complete blood count (CBC), which may show abnormal blood counts or blasts. A bone marrow aspiration and biopsy confirms the diagnosis. Flow cytometry identifies the leukemia type, and genetic tests look for changes that guide risk grouping. A lumbar puncture checks the spinal fluid.
Treatment Advances Behind Better Survival
Risk-Adapted Chemotherapy
Childhood ALL treatment runs in phases: induction to achieve remission, consolidation and intensification to clear remaining cells, and a long, gentler maintenance phase. Altogether it usually lasts two to three years. Treatment directed at the central nervous system prevents relapse in the brain, and for most children this is now done with spinal-fluid chemotherapy rather than cranial radiation.
Targeted and Immune Therapies
For Philadelphia chromosome-positive ALL, adding a tyrosine kinase inhibitor to chemotherapy has transformed a once very poor prognosis. For relapsed or resistant B-cell ALL, blinatumomab, an antibody that links T cells to leukemia cells, and CAR T-cell therapy, which reprograms a child’s own T cells, offer new routes to remission.
In AML, intensive chemotherapy remains the backbone, with targeted drugs for mutations such as FLT3 and hematopoietic stem cell transplantation for higher-risk or relapsed disease. Our overview of advances in leukemia survival covers these therapies in more depth.
Supportive Care
Many lives are saved not by the anticancer drugs themselves but by preventing and treating infections, transfusing blood products, and managing nutrition. Psychological and educational support helps children and families get through a long treatment course.
Life After Treatment
Survivors need long-term follow-up. Depending on treatment, late effects can include heart problems from anthracyclines, reduced bone density, fertility issues, learning difficulties, and a small risk of second cancers. Survivorship clinics monitor these so problems are caught early. A major aim of current research is to keep cure rates high while reducing these late effects.
When to See a Doctor
See your child’s doctor if they have unexplained bruising, tiny red spots on the skin (petechiae), persistent pallor or fatigue, recurrent fevers, bone pain that wakes them, or swollen lymph nodes that do not settle. Most of the time these have a simple explanation, but a blood count is quick and can rule out leukemia.
Frequently Asked Questions
What is the survival rate for childhood leukemia?
For ALL, around 90% of children in high-income countries survive five years or more, and most are cured. For AML, the figure is around two-thirds. Individual outlook depends on type, genetics, and response to treatment.
Is childhood leukemia curable?
Yes. Most children with ALL are cured with chemotherapy alone, and many with AML are cured with chemotherapy, with or without a stem cell transplant.
What happens if leukemia comes back?
Relapse is serious but often still treatable. Options include further chemotherapy, blinatumomab, CAR T-cell therapy, and stem cell transplantation, and some children are cured after relapse.
Why do survival rates differ between countries?
Survival depends on timely diagnosis, access to specialist treatment, and strong supportive care. Where these are limited, outcomes are lower, which is a major focus of global health efforts.
Key Takeaways
- Most children with leukemia now survive, with around 9 in 10 children with ALL cured in high-income countries.
- Age, white cell count, leukemia genetics, and early treatment response shape each child’s prognosis.
- Risk-adapted chemotherapy, targeted drugs, immune therapies, and supportive care drove the improvement.
- Long-term follow-up protects survivors from late effects. See our leukemia guide and the perspectives on leukemia survival rates for more.
